Levoamphetamine Explained

Levoamphetamine is a stimulant medication which is used in the treatment of certain medical conditions.[1] It was previously marketed by itself under the brand name Cydril, but is now available only in combination with dextroamphetamine in varying ratios under brand names like Adderall and Evekeo.[2] The drug is known to increase wakefulness and concentration in association with decreased appetite and fatigue. Pharmaceuticals that contain levoamphetamine are currently indicated and prescribed for the treatment of attention deficit hyperactivity disorder (ADHD), obesity, and narcolepsy in some countries.[3] Levoamphetamine is taken by mouth.

Levoamphetamine acts as a releasing agent of the monoamine neurotransmitters norepinephrine and dopamine. It is similar to dextroamphetamine in its ability to release norepinephrine and in its sympathomimetic effects but is a few times weaker than dextroamphetamine in its capacity to release dopamine and in its psychostimulant effects. Levoamphetamine is the levorotatory stereoisomer of the racemic amphetamine molecule, whereas dextroamphetamine is the dextrorotatory isomer.

Levoamphetamine was first introduced in the form of racemic amphetamine under the brand name Benzedrine in 1935 and as an enantiopure drug under the brand name Cydril in the 1970s. While pharmaceutical formulations containing enantiopure levoamphetamine are no longer manufactured, levomethamphetamine (levmetamfetamine) is still marketed and sold over-the-counter as a nasal decongestant.[4] In addition to being used in pharmaceutical drugs itself, levoamphetamine is a known active metabolite of certain other drugs, such as selegiline (L-deprenyl).[5]

Medical uses

Levoamphetamine has been used in the treatment of attention deficit hyperactivity disorder (ADHD) both alone and in combination with dextroamphetamine at different ratios. Levoamphetamine on its own has been found to be effective in the treatment of ADHD in multiple clinical studies conducted in the 1970s. The clinical dosages and potencies of levoamphetamine and dextroamphetamine in the treatment of ADHD have been fairly similar in these older studies.

Available forms

Racemic amphetamine

The first patented amphetamine brand, Benzedrine, was a racemic (i.e., equal parts) mixture of the free bases or the more stable sulfate salts of both amphetamine enantiomers (levoamphetamine and dextroamphetamine) that was introduced in the United States in 1934 as an inhaler for treating nasal congestion.[6] It was later realized that the amphetamine enantiomers could treat obesity, narcolepsy, and ADHD. Because of the greater central nervous system effect of the dextrorotatory enantiomer (i.e., dextroamphetamine), sold as Dexedrine, prescription of the Benzedrine brand fell and was eventually discontinued.[7] However, in 2012, racemic amphetamine sulfate was reintroduced as the Evekeo brand name.[8]

Adderall

Adderall is a 3.1:1 mixture of dextro- to levo- amphetamine base equivalent pharmaceutical that contains equal amounts (by weight) of four salts: dextroamphetamine sulfate, amphetamine sulfate, dextroamphetamine saccharate and amphetamine (D,L)-aspartate monohydrate. This result is a 76% dextroamphetamine to 24% levoamphetamine, or to ratio.[9] [10]

Evekeo

Evekeo is an FDA-approved medication that contains racemic amphetamine sulfate (i.e., 50% levoamphetamine sulfate and 50% dextroamphetamine sulfate).[11] It is approved for the treatment of narcolepsy, ADHD, and exogenous obesity. The orally disintegrating tablets are approved for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged six to 17 years of age.[12]

Other forms

Products using amphetamine base are now marketed. Dyanavel XR, a liquid suspension form became available in 2015, and contains about 24% levoamphetamine.[13] Adzenys XR, an orally dissolving tablet came to market in 2016 and contains 25% levoamphetamine.[14] [15]

Side effects

Levoamphetamine can produce sympathomimetic side effects.

Pharmacology

Pharmacodynamics

Levoamphetamine, similarly to dextroamphetamine, acts as a reuptake inhibitor and releasing agent of norepinephrine and dopamine in vitro. However, there are differences in potency between the two compounds. Levoamphetamine is either similar in potency or somewhat more potent in inducing the release of norepinephrine than dextroamphetamine, whereas dextroamphetamine is approximately 4-fold more potent in inducing the release of dopamine than levoamphetamine. In addition, as a reuptake inhibitor, levoamphetamine is about 3- to 7-fold less potent than dextroamphetamine in inhibiting dopamine reuptake but is only about 2-fold less potent in inhibiting norepinephrine reuptake. Dextroamphetamine is very weak as a reuptake inhibitor of serotonin, whereas levoamphetamine is essentially inactive in this regard. Levoamphetamine and dextroamphetamine are both also relatively weak reversible inhibitors of monoamine oxidase (MAO) and hence can inhibit catecholamine metabolism.[16] [17] However, this action may not occur significantly at clinical doses and may only be relevant to high doses.[18]

In rodent studies, both dextroamphetamine and levoamphetamine dose-dependently induce the release of dopamine in the striatum and norepinephrine in the prefrontal cortex. Dextroamphetamine is about 3- to 5-fold more potent in increasing striatal dopamine levels as levoamphetamine in rodents in vivo, whereas the two enantiomers are about equally effective in terms of increasing prefrontal norepinephrine levels. Dextroamphetamine has greater effects on dopamine levels than on norepinephrine levels, whereas levoamphetamine has relatively more balanced effects on dopamine and norepinephrine levels. As with rodent studies, levoamphetamine and dextroamphetamine have been found to be similarly potent in elevating norepinephrine levels in cerebrospinal fluid in monkeys.[19] [20] By an uncertain mechanism, the striatal dopamine release of dextroamphetamine in rodents appears to be prolonged by levoamphetamine when the two enantiomers are administered at a 3:1 ratio (though not at a 1:1 ratio).

The catecholamine-releasing effects of levoamphetamine and dextroamphetamine in rodents have a fast onset of action, with a peak of effect after about 30 to 45minutes, are large in magnitude (e.g., 700–1,500% of baseline for dopamine and 400–450% of baseline for norepinephrine), and decline relatively rapidly after the effects reach their maximum. The magnitudes of the effects of amphetamines are greater than those of classical reuptake inhibitors like atomoxetine and bupropion. In addition, unlike with reuptake inhibitors, there is no dose–effect ceiling in the case of amphetamines. Although dextroamphetamine is more potent than levoamphetamine, both enantiomers can maximally increase striatal dopamine release by more than 5,000% of baseline.[21] This is in contrast to reuptake inhibitors like bupropion and vanoxerine, which have 5- to 10-fold smaller maximal impacts on dopamine levels and, in contrast to amphetamines, were not experienced as stimulating or euphoric.

Dextroamphetamine has greater potency in producing stimulant-like effects in rodents and non-human primates than levoamphetamine. Some rodent studies have found it to be 5- to 10-fold more potent in its stimulant-like effects than levoamphetamine.[22] [23] [24] Levoamphetamine is also less potent than dextroamphetamine in its anorectic effects in rodents.[25] Dextroamphetamine is about 4-fold more potent than levoamphetamine in motivating self-administration in monkeys and is about 2- to 3-fold more potent than levoamphetamine in terms of positive reinforcing effects in humans.[26] Potency ratios of dextroamphetamine versus levoamphetamine with single doses of 5 to 80mg in terms of psychological effects in humans including stimulation, wakefulness, activation, euphoria, reduction of hyperactivity, and exacerbation of psychosis have ranged from 1:1 to 4:1 in a variety of older clinical studies.[27] [28] With very large doses, ranging from 270 to 640mg, the potency ratios of dextroamphetamine and levoamphetamine in stimulating locomotor activity and inducing amphetamine psychosis in humans have ranged from 1:1 to 2:1 in a couple studies. The differences in potency and dopamine versus norepinephrine release between dextroamphetamine and levoamphetamine are suggestive of dopamine being the primary neurochemical mediator responsible for the stimulant and euphoric effects of these agents.

In addition to inducing norepinephrine release in the brain, levoamphetamine and dextroamphetamine induce the release of epinephrine (adrenaline) in the peripheral sympathetic nervous system and this is related to their cardiovascular effects. Although levoamphetamine is less potent than dextroamphetamine as a stimulant, it is approximately equipotent with dextroamphetamine in producing various peripheral effects, including vasoconstriction, vasopression, and other cardiovascular effects.

Similarly to dextroamphetamine, levoamphetamine has been found to improve symptoms in a animal model of ADHD, the spontaneously hypertensive rat (SHR), including improving sustained attention and reducing overactivity and impulsivity.[29] [30] [31] [32] These findings parallel the clinical results in which both levoamphetamine and dextroamphetamine have been found to be effective in the treatment of ADHD in humans.

Unlike the case of dextroamphetamine versus dextromethamphetamine, in which the latter is more effective than the former, levoamphetamine is substantially more potent as a dopamine releaser and stimulant than levomethamphetamine.[33] Conversely, levoamphetamine, levomethamphetamine, and dextroamphetamine are all similar in their potencies as norepinephrine releasers.

In addition to its catecholamine-releasing activity, levoamphetamine is also an agonist of the trace amine-associated receptor 1 (TAAR1).[34] [35] Levoamphetamine has also been found to act as a catecholaminergic activity enhancer (CAE), notably at much lower concentrations than its catecholamine releasing activity.[36] [37] [38] It is similarly potent to selegiline and levomethamphetamine but is more potent than dextromethamphetamine and dextroamphetamine in this action. The CAE effects of such agents may be mediated by TAAR1 agonism.[39]

Pharmacokinetics

The pharmacokinetics of levoamphetamine have been studied. Usually this has been orally in combination with dextroamphetamine at different ratios. The pharmacokinetics of levoamphetamine have also been studied as a metabolite of selegiline.

Absorption

The oral bioavailability of levoamphetamine has been found to be similar to that of dextroamphetamine.

The time to peak levels of levoamphetamine with immediate-release (IR) formulations of amphetamine ranges from 2.5 to 3.5hours and with extended-release (ER) formulations ranges from 5.3 to 8.2hours depending on the formulation and the study.[40] For comparison, the time to peak levels of dextroamphetamine with IR formulations ranges from 2.4 to 3.3hours and with ER formulations ranges from 4.0 to 8.0hours. The peak levels of levoamphetamine are proportionally similar to those of dextroamphetamine with administration of amphetamine at varying ratios. With a single oral dose of 10mg racemic amphetamine (a 1:1 ratio of enantiomers, or 5mg dextroamphetamine and 5mg levoamphetamine), peak levels of dextroamphetamine were 14.7ng/mL and peak levels of levoamphetamine were 12.0ng/mL in one study.

Food does not affect the peak levels or overall exposure to levoamphetamine or dextroamphetamine with IR racemic amphetamine. However, time to peak levels was delayed from 2.5hours (range 1.5–6hours) to 4.5hours (range 2.5–8.0hours).

During oral selegiline therapy at a dosage of 10mg/day, circulating levels of levoamphetamine have been found to be 6 to 8ng/mL and levels of levomethamphetamine have been reported to be 9 to 14ng/mL. Although levels of levoamphetamine and levomethamphetamine are relatively low at typical doses of selegiline, they could be clinically relevant and may contribute to the effects and side effects of selegiline.

Distribution

The volume of distribution of both levoamphetamine and dextroamphetamine is about 3 to 4L/kg.

The plasma protein binding of levoamphetamine is 31.7%, whereas that of dextroamphetamine was 29.0% in the same study.[41]

Metabolism

Levoamphetamine and dextroamphetamine are metabolized via CYP2D6-mediated hydroxylation to produce 4-hydroxyamphetamine and additionally via oxidative deamination. There are several enzymes involved in the metabolism of amphetamine, of which CYP2D6 is one. Levoamphetamine seems to be metabolized somewhat less efficiently than dextroamphetamine.

The pharmacokinetics of levoamphetamine generated as a metabolite from selegiline have been found not to significantly vary in CYP2D6 poor metabolizers versus extensive metabolizers, suggesting that CYP2D6 may be minimally involved in the clinical metabolism of levoamphetamine.[42] [43]

Elimination

The mean elimination half-life of levoamphetamine ranges from 11.7 to 15.2hours in different studies. Its half-life is somewhat longer than that of dextroamphetamine, with a difference of about 1 to 2hours. For comparison, in the same studies that reported the preceding values for levoamphetamine's half-life, the half-life of dextroamphetamine ranged from 10.0 to 12.4hours.

The elimination of amphetamine is highly dependent on urinary pH.[44] Urinary acidifying agents like ascorbic acid and ammonium chloride increase amphetamine excretion and reduce its elimination half-life, whereas urinary alkalinizing agents like acetazolamide enhance renal tubular reabsorption and extend its half-life. The urinary excretion of unchanged amphetamine is 70% on average with a urinary pH of 6.6 and 17 to 43% at a urinary pH of greater than 6.7.

With selegiline at a oral dose of 10mg, levoamphetamine and levomethamphetamine are eliminated in urine and recovery of levoamphetamine is 9 to 30% (or about 1–3mg) while that of levomethamphetamine is 20 to 60% (or about 2–6mg).

Chemistry

Levoamphetamine is a substituted phenethylamine and amphetamine. It is also known as L-α-methyl-β-phenylethylamine or as (2R)-1-phenylpropan-2-amine. Levoamphetamine is the levorotatory stereoisomer of the amphetamine molecule. Racemic amphetamine contains two optical isomers in equal amounts, dextroamphetamine (the dextrorotatory enantiomer) and levoamphetamine.

History

The origin of the amphetamine psychostimulants comes from ephedra. This plant, also known as "ma huang", is an herb which has been used for thousands of years in traditional Chinese medicine as a stimulant and antiasthmatic medicine.[45] [46] Ephedrine ((1R,2S)-β-hydroxy-N-methylamphetamine), an analogue and derivative of amphetamine and the major pharmacologically active constituent of ephedra, was first isolated from the plant in 1885.[47] [48] Another plant, known as Catha edulis (khat), also naturally contains amphetamines, specifically cathine ((1S,2S)-β-hydroxyamphetamine) and cathinone (β-ketoamphetamine). It has a long history of use for its stimulant effects in Eastern Africa and the Arabian Peninsula.[49] However, cathine was not isolated from khat until 1930 and cathinone was not isolated from the plant until 1975.

Amphetamine, which is a racemic mixture of dextroamphetamine and levoamphetamine, was first discovered in 1887, shortly after the isolation of ephedrine.[50] However, it was not until 1927 that amphetamine was synthesized by Gordon Alles and was studied by him in animals and humans. This led to the discovery of the stimulating effects of amphetamine in humans in 1929 after Alles injected himself with 50mg of the drug. Levoamphetamine was first introduced in the form of racemic amphetamine (a 1:1 combination of levoamphetamine and dextroamphetamine) under the brand name Benzedrine in 1935. It was indicated for the treatment of narcolepsy, mild depression, parkinsonism, and a variety of other conditions. Dextroamphetamine was found to be the more potent of the two enantiomers of amphetamine and was introduced as an enantiopure drug under the brand name Dexedrine in 1937. Consequent to its lower potency, levoamphetamine has received far less attention than racemic amphetamine or dextroamphetamine.

Levoamphetamine was studied in the treatment of attention deficit hyperactivity disorder (ADHD) in the 1970s and was found to be clinically effective for this condition similarly to dextroamphetamine. As a result, it was marketed as an enantiopure drug under the brand name Cydril for the treatment of ADHD in the 1970s.[51] However, it was reported in 1976 that racemic amphetamine was less effective than dextroamphetamine in treating ADHD. As a result of this study, use of racemic amphetamine in the treatment of ADHD dramatically declined in favor of dextroamphetamine. Enantiopure levoamphetamine was eventually discontinued and is no longer available today.

Society and culture

Recreational use

Misuse of enantiopure levoamphetamine and levomethamphetamine is reportedly not known. However, rare cases of misuse of levomethamphetamine, which is available over-the-counter as a nasal decongestant, actually have been reported.[52] [53] [54] [55] Due to their lower efficacy in stimulating dopamine release and their reduced potency as psychostimulants, levoamphetamine and levomethamphetamine would theoretically be expected to have less misuse potential than the corresponding dextroamphetamine and dextromethamphetamine forms.

Research

Levoamphetamine as an enantiopure drug has been studied in the past in a variety of contexts.[56] These include its effects in and/or treatment of mood, "minimal brain dysfunction",[57] narcolepsy,[58] "hyperkinetic syndrome" and aggression,[59] [60] sleep,[61] [62] schizophrenia,[63] wakefulness,[64] Tourette's syndrome,[65] and Parkinson's disease, among others.[66] Levoamphetamine has been studied in the treatment of multiple sclerosis in more modern studies and has been reported to improve cognition and memory in this condition as well.[67] [68] [69] [70] [71] [72]

Other drugs

Selegiline

See main article: Selegiline.

Levoamphetamine is a major active metabolite of selegiline (L-deprenyl; N-propargyl-L-methamphetamine). Selegiline is a monoamine oxidase inhibitor (MAOI), specifically a selective inhibitor of monoamine oxidase B (MAO-B) at lower doses and a dual inhibitor of both monoamine oxidase A (MAO-A) and MAO-B at higher doses.[73] It also has additional activities, such as acting as a catecholaminergic activity enhancer (CAE), possibly via agonism of the TAAR1, and having potential neuroprotective effects.[74] Selegiline is clinically used as an antiparkinsonian agent in the treatment of Parkinson's disease and as an antidepressant in the treatment of major depressive disorder.[75]

In addition to levoamphetamine, selegiline also metabolizes into levomethamphetamine. With a 10mg oral dose of selegiline, about 2 to 6mg levomethamphetamine and 1 to 3mg levoamphetamine is excreted in urine.[76] [77] [78] As levoamphetamine and levomethamphetamine are norepinephrine and/or dopamine releasing agents, they may contribute to the effects and side effects of selegiline.[79] [80] [81] This may particularly include cardiovascular and sympathomimetic effects of selegiline.[82] [83] [84] Other selective MAO-B inhibitors that do not metabolize into amphetamine metabolites or have associated cardiovascular effects, such as rasagiline, have also been developed and introduced.[85]

Because selegiline metabolizes into levoamphetamine and levomethamphetamine, people taking selegiline can erroneously test positive for amphetamines on drug tests.[86] [87]

External links

Notes and References

  1. Heal DJ, Smith SL, Gosden J, Nutt DJ . Amphetamine, past and present--a pharmacological and clinical perspective . J Psychopharmacol . 27 . 6 . 479–496 . June 2013 . 23539642 . 3666194 . 10.1177/0269881113482532 .
  2. Markowitz JS, Patrick KS . The Clinical Pharmacokinetics of Amphetamines Utilized in the Treatment of Attention-Deficit/Hyperactivity Disorder . J Child Adolesc Psychopharmacol . 27 . 8 . 678–689 . October 2017 . 28910145 . 10.1089/cap.2017.0071 .
  3. Book: Simola N, Carta M . Neuropathology of Drug Addictions and Substance Misuse . Amphetamine Usage, Misuse, and Addiction Processes . Elsevier . 2016 . 978-0-12-800212-4 . 10.1016/b978-0-12-800212-4.00002-9 . 14–24.
  4. Barkholtz HM, Hadzima R, Miles A . Pharmacology of R-(-)-Methamphetamine in Humans: A Systematic Review of the Literature . ACS Pharmacol Transl Sci . 6 . 7 . 914–924 . July 2023 . 37470013 . 10353062 . 10.1021/acsptsci.3c00019 .
  5. Heinonen EH, Lammintausta R . A review of the pharmacology of selegiline . Acta Neurol Scand Suppl . 136 . 44–59 . 1991 . 1686954 . 10.1111/j.1600-0404.1991.tb05020.x .
  6. Heal DJ, Smith SL, Gosden J, Nutt DJ . Amphetamine, past and present – a pharmacological and clinical perspective . J. Psychopharmacol. . 27 . 6 . 479–496 . June 2013 . 23539642 . 3666194 . 10.1177/0269881113482532.
  7. Web site: Benzedrine: FDA-Approved Drugs . U.S. Food and Drug Administration (FDA) . 4 September 2015.
  8. Web site: Evekeo: FDA-Approved Drugs . U.S. Food and Drug Administration (FDA) . 11 August 2015.
  9. Web site: Adderall XR- dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine sulfate and amphetamine aspartate capsule, extended release . DailyMed . 17 July 2019 . 7 April 2020.
  10. Web site: Adderall- dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablet . DailyMed . 8 November 2019 . 7 April 2020.
  11. Web site: Evekeo- amphetamine sulfate tablet . DailyMed . 14 August 2019 . 7 April 2020.
  12. Web site: Evekeo ODT- amphetamine sulfate tablet, orally disintegrating . DailyMed . 20 February 2020 . 7 April 2020.
  13. Web site: Dyanavel XR Prescribing Information . 14 May 2017. January 2017.
  14. Web site: Adzenys XR-ODT- amphetamine tablet, orally disintegrating . DailyMed . 22 January 2020 . 7 April 2020 .
  15. Web site: Adzenys ER- amphetamine suspension, extended release . DailyMed . 21 January 2020 . 7 April 2020.
  16. Clarke D . Amphetamine and monoamine oxidase inhibition: an old idea gains new acceptance . Trends in Pharmacological Sciences . 1 . 2 . 1980 . 10.1016/0165-6147(80)90032-2 . 312–313.
  17. Miller HH, Clarke DE . In vitro inhibition of monoamine oxidase types A and B by d- and l-amphetamine . Communications in Psychopharmacology . 2 . 4 . 319–325 . 1978 . 729356 .
  18. Book: Nishino S, Kotorii N . Narcolepsy: A Clinical Guide . 2 . Modes of Action of Drugs Related to Narcolepsy: Pharmacology of Wake-Promoting Compounds and Anticataplectics . Springer International Publishing . Cham . 2016 . 978-3-319-23738-1 . 10.1007/978-3-319-23739-8_22 . 307–329 .
  19. Book: Ziegler MG . Handbook of Research Methods in Cardiovascular Behavioral Medicine . Catecholamine Measurement in Behavioral Research . Springer US . Boston, MA . 1989 . 978-1-4899-0908-4 . 10.1007/978-1-4899-0906-0_11 . 167–183.
  20. Ziegler MG, Lake CR, Ebert MH . Norepinephrine elevations in cerebrospinal fluid after d- and l-amphetamine . European Journal of Pharmacology . 57 . 2–3 . 127–133 . August 1979 . 114399 . 10.1016/0014-2999(79)90358-3 .
  21. The SH rat model of ADHD has profoundly different catecholaminergic responses to amphetamine's enantiomers compared with Sprague-Dawleys . Cheetham SC, Kulkarni RS, Rowley HL, Heal DJ . 2007 . Neuroscience 2007, San Diego, CA, Nov 3-7, 2007 . https://www.abstractsonline.com/pp8/#!/1820 . Society for Neuroscience . https://archive.today/20240727180222/https://www.abstractsonline.com/pp8/%23!/1820/presentation/12987 . 27 July 2024 . Both d- and l-[amphetamine (AMP)] evoked rapid increases in extraneuronal concentrations of [noradrenaline (NA)] and [dopamine (DA)] that reached a maximum 30 or 60 min after administration. However, the [spontaneously hypertensive rats (SHRs)] were much more responsive to AMP's enantiomers than the [Sprague-Dawleys (SDs)]. Thus, 3 mg/kg d-AMP produced a peak increase in [prefrontal cortex (PFC)] NA of 649 ± 87% (p<0.001) in SHRs compared with 198 ± 39% (p<0.05) in SDs; the corresponding figures for [striatal (STR)] DA were 4898 ± 1912% (p<0.001) versus 1606 ± 391% (p<0.001). At 9 mg/kg, l-AMP maximally increased NA efflux by 1069 ± 105% (p<0.001) in SHRs compared with 157 ± 24% (p<0.01) in SDs; the DA figures were 3294 ± 691% (p<0.001) versus 459 ± 107% (p<0.001)..
  22. Book: Biel JH, Bopp BA . Stimulants . Amphetamines: Structure-Activity Relationships . Springer US . Boston, MA . 1978 . 978-1-4757-0512-6 . 10.1007/978-1-4757-0510-2_1 . 1–39 .
  23. Segal DS . Behavioral characterization of d- and l-amphetamine: neurochemical implications . Science . 190 . 4213 . 475–477 . October 1975 . 1166317 . 10.1126/science.1166317 . 1975Sci...190..475S .
  24. Taylor KM, Snyder SH . Amphetamine: differentiation by d and l isomers of behavior involving brain norepinephrine or dopamine . Science . 168 . 3938 . 1487–1489 . June 1970 . 5463064 . 10.1126/science.168.3938.1487 . 1970Sci...168.1487T .
  25. Lawlor RB, Trivedi MC, Yelnosky J . A determination of the anorexigenic potential of dl-amphetamine, d-amphetamine, l-amphetamine and phentermine . Arch Int Pharmacodyn Ther . 179 . 2 . 401–407 . June 1969 . 5367311 .
  26. Balster RL, Schuster CR . A comparison of d-amphetamine, l-amphetamine, and methamphetamine self-administration in rhesus monkeys . Pharmacol Biochem Behav . 1 . 1 . 67–71 . 1973 . 4204513 . 10.1016/0091-3057(73)90057-9 .
  27. Smith RC, Davis JM . Comparative effects of d-amphetamine, l-amphetamine, and methylphenidate on mood in man . Psychopharmacology (Berl) . 53 . 1 . 1–12 . June 1977 . 407607 . 10.1007/BF00426687 .
  28. Van Kammen DP, Murphy DL . Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment . Psychopharmacologia . 44 . 3 . 215–224 . November 1975 . 1824 . 10.1007/BF00428897 .
  29. Kantak KM . Rodent models of attention-deficit hyperactivity disorder: An updated framework for model validation and therapeutic drug discovery . Pharmacol Biochem Behav . 216 . 173378 . May 2022 . 35367465 . 10.1016/j.pbb.2022.173378 .
  30. Book: Teal LB, Ingram SM, Bubser M, McClure E, Jones CK . Drug Development in Psychiatry . The Evolving Role of Animal Models in the Discovery and Development of Novel Treatments for Psychiatric Disorders . Advances in Neurobiology . Springer International Publishing . Cham . 30 . 2023 . 978-3-031-21053-2 . 10.1007/978-3-031-21054-9_3 . 37–99. 36928846 .
  31. Sagvolden T . Impulsiveness, overactivity, and poorer sustained attention improve by chronic treatment with low doses of l-amphetamine in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD) . Behav Brain Funct . 7 . 6 . March 2011 . 21450079 . 3086861 . 10.1186/1744-9081-7-6 . free .
  32. Sagvolden T, Xu T . l-Amphetamine improves poor sustained attention while d-amphetamine reduces overactivity and impulsiveness as well as improves sustained attention in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD) . Behav Brain Funct . 4 . 3 . January 2008 . 18215285 . 2265273 . 10.1186/1744-9081-4-3 . free .
  33. Kuczenski R, Segal DS, Cho AK, Melega W . Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine . J Neurosci . 15 . 2 . 1308–1317 . February 1995 . 7869099 . 6577819 . 10.1523/JNEUROSCI.15-02-01308.1995 .
  34. Sotnikova TD, Caron MG, Gainetdinov RR . Trace amine-associated receptors as emerging therapeutic targets . Mol Pharmacol . 76 . 2 . 229–35 . August 2009 . 19389919 . 2713119 . 10.1124/mol.109.055970 . Intriguingly, d- and l-amphetamine, methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA), and other closely related compounds are also able to activate TAAR1 receptors in vitro as evidenced by cAMP stimulation in human embryonic kidney cells..
  35. Reese EA, Norimatsu Y, Grandy MS, Suchland KL, Bunzow JR, Grandy DK . Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine . J Med Chem . 57 . 2 . 378–390 . January 2014 . 24354319 . 10.1021/jm401316v .
  36. Knoll J . Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain . CNS Drug Rev . 7 . 3 . 317–45 . 2001 . 11607046 . 6494119 . 10.1111/j.1527-3458.2001.tb00202.x .
  37. Knoll J . (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain . Pharmacol Toxicol . 82 . 2 . 57–66 . February 1998 . 9498233 . 10.1111/j.1600-0773.1998.tb01399.x .
  38. Knoll J, Miklya I . Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition . Arch Int Pharmacodyn Ther . 328 . 1 . 1–15 . 1994 . 7893186 .
  39. Harsing LG, Knoll J, Miklya I . Enhancer Regulation of Dopaminergic Neurochemical Transmission in the Striatum . Int J Mol Sci . 23 . 15 . August 2022 . 8543 . 35955676 . 9369307 . 10.3390/ijms23158543 . free .
  40. Markowitz JS, Melchert PW . The Pharmacokinetics and Pharmacogenomics of Psychostimulants . Child Adolesc Psychiatr Clin N Am . 31 . 3 . 393–416 . July 2022 . 35697392 . 10.1016/j.chc.2022.03.003 .
  41. Losacker M, Roehrich J, Hess C . Enantioselective determination of plasma protein binding of common amphetamine-type stimulants . J Pharm Biomed Anal . 205 . 114317 . October 2021 . 34419812 . 10.1016/j.jpba.2021.114317 .
  42. Kraemer T, Maurer HH . Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives . Ther Drug Monit . 24 . 2 . 277–89 . April 2002 . 11897973 . 10.1097/00007691-200204000-00009 .
  43. Scheinin H, Anttila M, Dahl ML, Karnani H, Nyman L, Taavitsainen P, Pelkonen O, Bertilsson L . CYP2D6 polymorphism is not crucial for the disposition of selegiline . Clin Pharmacol Ther . 64 . 4 . 402–411 . October 1998 . 9797797 . 10.1016/S0009-9236(98)90071-6 .
  44. Patrick KS, Markowitz JS . Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder . Human Psychopharmacology: Clinical and Experimental . 12 . 6 . 1997 . 0885-6222 . 10.1002/(SICI)1099-1077(199711/12)12:6<527::AID-HUP932>3.0.CO;2-U . 527–546.
  45. Abourashed EA, El-Alfy AT, Khan IA, Walker L . Ephedra in perspective--a current review . Phytother Res . 17 . 7 . 703–712 . August 2003 . 12916063 . 10.1002/ptr.1337 .
  46. Kalix P . The pharmacology of psychoactive alkaloids from ephedra and catha . J Ethnopharmacol . 32 . 1–3 . 201–208 . April 1991 . 1881158 . 10.1016/0378-8741(91)90119-x .
  47. Aaron CK . Sympathomimetics . Emerg Med Clin North Am . 8 . 3 . 513–526 . August 1990 . 2201518 . 10.1016/S0733-8627(20)30256-X.
  48. Morelli M, Tognotti E . Brief history of the medical and non-medical use of amphetamine-like psychostimulants . Exp Neurol . 342 . 113754 . August 2021 . 34000249 . 10.1016/j.expneurol.2021.113754 .
  49. Patel NB . Mechanism of action of cathinone: the active ingredient of khat (Catha edulis) . East Afr Med J . 77 . 6 . 329–332 . June 2000 . 12858935 . 10.4314/eamj.v77i6.46651 .
  50. Rasmussen N . Amphetamine-Type Stimulants: The Early History of Their Medical and Non-Medical Uses . Int Rev Neurobiol . 120 . 9–25 . 2015 . 26070751 . 10.1016/bs.irn.2015.02.001 .
  51. Arnold LE, Wender PH, McCloskey K, Snyder SH . Levoamphetamine and dextroamphetamine: comparative efficacy in the hyperkinetic syndrome. Assessment by target symptoms . Arch Gen Psychiatry . 27 . 6 . 816–22 . December 1972 . 4564954 . 10.1001/archpsyc.1972.01750300078015 .
  52. Mendelson JE, McGlothlin D, Harris DS, Foster E, Everhart T, Jacob P, Jones RT . The clinical pharmacology of intranasal l-methamphetamine . BMC Clin Pharmacol . 8 . 4 . July 2008 . 18644153 . 2496900 . 10.1186/1472-6904-8-4 . free .
  53. Gal J . Amphetamines in Nasal Inhalers . Journal of Toxicology: Clinical Toxicology . 19 . 5 . 1982 . 0731-3810 . 10.3109/15563658208992508 . 517–518.
  54. Halle AB, Kessler R, Alvarez M . Drug abuse with Vicks nasal inhaler . South Med J . 78 . 6 . 761–2 . June 1985 . 4002016 . 10.1097/00007611-198506000-00043 .
  55. Ferrando RL, McCorvey E, Simon WA, Stewart DM . Bizarre behavior following the ingestion of levo-desoxyephedrine . Drug Intell Clin Pharm . 22 . 3 . 214–217 . March 1988 . 3366062 . 10.1177/106002808802200308 .
  56. Book: Silverstone T, Wells B . Amphetamines and Related Stimulants: Chemical, Biological, Clinical, and Sociological Aspects . Clinical Psychopharmacology of Amphetamine and Related Compounds . CRC Press . 1980 . 978-0-429-27984-3 . 10.1201/9780429279843-10 . 147–160.
  57. Arnold LE, Huestis RD, Smeltzer DJ, Scheib J, Wemmer D, Colner G . Levoamphetamine vs dextroamphetamine in minimal brain dysfunction. Replication, time response, and differential effect by diagnostic group and family rating . Arch Gen Psychiatry . 33 . 3 . 292–301 . March 1976 . 769721 . 10.1001/archpsyc.1976.01770030012002 .
  58. Parkes JD, Fenton GW . Levo(-) amphetamine and dextro(+) amphetamine in the treatment of narcolepsy . J Neurol Neurosurg Psychiatry . 36 . 6 . 1076–81 . December 1973 . 4359162 . 1083612 . 10.1136/jnnp.36.6.1076 .
  59. Arnold LE, Kirilcuk V, Corson SA, Corson EO . Levoamphetamine and dextroamphetamine: differential effect on aggression and hyperkinesis in children and dogs . Am J Psychiatry . 130 . 2 . 165–70 . February 1973 . 4568123 . 10.1176/ajp.130.2.165 .
  60. Arnold LE, Wender PH, McCloskey K, Snyder SH . Levoamphetamine and dextroamphetamine: comparative efficacy in the hyperkinetic syndrome. Assessment by target symptoms . Arch Gen Psychiatry . 27 . 6 . 816–22 . December 1972 . 4564954 . 10.1001/archpsyc.1972.01750300078015 .
  61. Gillin JC, van Kammen DP, Graves J, Murphy D . Differential effects of D- and L-amphetamine on the sleep of depressed patients . Life Sci . 17 . 8 . 1223–1240 . October 1975 . 172755 . 10.1016/0024-3205(75)90132-0 .
  62. Hartmann E, Cravens J . Sleep: effects of d- and l-amphetamine in man and in rat . Psychopharmacology (Berl) . 50 . 2 . 171–175 . November 1976 . 826958 . 10.1007/BF00430488 .
  63. Janowsky DS, Davis JM . Methylphenidate, dextroamphetamine, and levamfetamine. Effects on schizophrenic symptoms . Arch Gen Psychiatry . 33 . 3 . 304–308 . March 1976 . 769722 . 10.1001/archpsyc.1976.01770030024003 .
  64. Hartmann E, Orzack MH, Branconnier R . Sleep deprivation deficits and their reversal by d- and l-amphetamine . Psychopharmacology (Berl) . 53 . 2 . 185–189 . July 1977 . 408844 . 10.1007/BF00426490 .
  65. Caine ED, Ludlow CL, Polinsky RJ, Ebert MH . Provocative drug testing in Tourette's syndrome: d- and l-amphetamine and haloperidol . J Am Acad Child Psychiatry . 23 . 2 . 147–152 . March 1984 . 6585416 . 10.1097/00004583-198403000-00005 .
  66. Parkes JD, Tarsy D, Marsden CD, Bovill KT, Phipps JA, Rose P, Asselman P . Amphetamines in the treatment of Parkinson's disease . J Neurol Neurosurg Psychiatry . 38 . 3 . 232–7 . March 1975 . 1097600 . 491901 . 10.1136/jnnp.38.3.232 .
  67. Patti F . Treatment of cognitive impairment in patients with multiple sclerosis . Expert Opin Investig Drugs . 21 . 11 . 1679–1699 . November 2012 . 22876911 . 10.1517/13543784.2012.716036 .
  68. Lovera J, Kovner B . Cognitive impairment in multiple sclerosis . Curr Neurol Neurosci Rep . 12 . 5 . 618–627 . October 2012 . 22791241 . 4581520 . 10.1007/s11910-012-0294-3 .
  69. Roy S, Benedict RH, Drake AS, Weinstock-Guttman B . Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis . CNS Drugs . 30 . 3 . 209–225 . March 2016 . 26884145 . 10.1007/s40263-016-0319-6 .
  70. Morrow SA, Kaushik T, Zarevics P, Erlanger D, Bear MF, Munschauer FE, Benedict RH . The effects of L-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial . J Neurol . 256 . 7 . 1095–102 . July 2009 . 19263186 . 10.1007/s00415-009-5074-x .
  71. Benedict RH, Munschauer F, Zarevics P, Erlanger D, Rowe V, Feaster T, Carpenter RL . Effects of l-amphetamine sulfate on cognitive function in multiple sclerosis patients . J Neurol . 255 . 6 . 848–852 . June 2008 . 18481035 . 10.1007/s00415-008-0760-7 .
  72. Sumowski JF, Chiaravalloti N, Erlanger D, Kaushik T, Benedict RH, DeLuca J . L-amphetamine improves memory in MS patients with objective memory impairment . Mult Scler . 17 . 9 . 1141–1145 . September 2011 . 21561956 . 10.1177/1352458511404585 .
  73. Miklya I . The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015) . Mol Psychiatry . 21 . 11 . 1499–1503 . November 2016 . 27480491 . 10.1038/mp.2016.127 .
  74. Harsing LG, Timar J, Miklya I . Striking Neurochemical and Behavioral Differences in the Mode of Action of Selegiline and Rasagiline . Int J Mol Sci . 24 . 17 . August 2023 . 13334 . 37686140 . 10487936 . 10.3390/ijms241713334 . free .
  75. Tábi T, Vécsei L, Youdim MB, Riederer P, Szökő É . Selegiline: a molecule with innovative potential . J Neural Transm (Vienna) . 127 . 5 . 831–842 . May 2020 . 31562557 . 7242272 . 10.1007/s00702-019-02082-0 .
  76. Poston KL, Waters C . Zydis selegiline in the management of Parkinson's disease . Expert Opin Pharmacother . 8 . 15 . 2615–2624 . October 2007 . 17931095 . 10.1517/14656566.8.15.2615 .
  77. Mahmood I . Clinical pharmacokinetics and pharmacodynamics of selegiline. An update . Clin Pharmacokinet . 33 . 2 . 91–102 . August 1997 . 9260033 . 10.2165/00003088-199733020-00002 .
  78. Chrisp P, Mammen GJ, Sorkin EM . Selegiline: A Review of its Pharmacology, Symptomatic Benefits and Protective Potential in Parkinson's Disease . Drugs Aging . 1 . 3 . 228–248 . May 1991 . 1794016 . 10.2165/00002512-199101030-00006 .
  79. Gerlach M, Reichmann H, Riederer P . A critical review of evidence for preclinical differences between rasagiline and selegiline . Basal Ganglia . 2 . 4 . 2012 . 10.1016/j.baga.2012.04.032 . S9–S15 .
  80. Book: Yasar S, Goldberg JP, Goldberg SR . Are metabolites of l-deprenyl (Selegiline) useful or harmful? Indications from preclinical research . Deprenyl — Past and Future . Journal of Neural Transmission. Supplementum . 61–73 . January 1, 1996 . 48 . 8988462 . 10.1007/978-3-7091-7494-4_6 . 978-3-211-82891-5 .
  81. Rothman RB, Baumann MH . Monoamine transporters and psychostimulant drugs . Eur J Pharmacol . 479 . 1–3 . 23–40 . October 2003 . 14612135 . 10.1016/j.ejphar.2003.08.054 .
  82. Finberg JP . Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease . Journal of Neural Transmission . 126 . 4 . 433–448 . April 2019 . 30386930 . 10.1007/s00702-018-1952-7 .
  83. Simpson LL . Evidence that deprenyl, A type B monoamine oxidase inhibitor, is an indirectly acting sympathomimetic amine . Biochem Pharmacol . 27 . 11 . 1591–1595 . 1978 . 697901 . 10.1016/0006-2952(78)90490-2 .
  84. Abassi ZA, Binah O, Youdim MB . Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline . Br J Pharmacol . 143 . 3 . 371–378 . October 2004 . 15339864 . 1575354 . 10.1038/sj.bjp.0705962 .
  85. Dezsi L, Vecsei L . Monoamine Oxidase B Inhibitors in Parkinson's Disease . CNS Neurol Disord Drug Targets . 16 . 4 . 425–439 . 2017 . 28124620 . 10.2174/1871527316666170124165222 .
  86. Musshoff F . Illegal or legitimate use? Precursor compounds to amphetamine and methamphetamine . Drug Metab Rev . 32 . 1 . 15–44 . February 2000 . 10711406 . 10.1081/dmr-100100562 .
  87. Cody JT . Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results . J Occup Environ Med . 44 . 5 . 435–450 . May 2002 . 12024689 . 10.1097/00043764-200205000-00012 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Levoamphetamine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.